Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03082287 · ClinicalTrials.gov registry record
ALPCO Calprotectin ELISA - Measurement of Calprotectin Levels in Human Stool
A clinical trial, sponsored by American Laboratory Products Company.
- Completed
- Registry status
- 424
- Enrollment target
NCT03082287: Completed study, sponsored by American Laboratory Products Company.
NCT03082287 is a clinical trial that has completed, run by American Laboratory Products Company. The registered enrollment target is 424 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03082287 has completed, sponsored by American Laboratory Products Company.
- COMPLETED
- Registry status
- 424 participants
- Enrollment target
Study Summary
The ALPCO Calprotectin ELISA is an in vitro diagnostic test intended to quantitatively measure concentrations of fecal calprotectin in human stool samples. Calprotectin is a protein biomarker of mucosal inflammation. Measurement of calprotectin can aid in the diagnosis of Inflammatory Bowel Diseases (IBD), specifically Crohn's Disease (CD) and Ulcerative Colitis (UC), as well as aid in the differentiation of IBD from Irritable Bowel Syndrome (IBS) when used in conjunction with other diagnostic testing and the total clinical picture. This study will estimate the predictive values of a negative (NPV) and positive (PPV) test by utilizing the assay outcomes of the ALPCO Calprotectin ELISA.
Primary Outcome
Value of calprotectin measurement in the ELISA
Interventions
- DEVICE Fecal Calprotectin Level
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2019-10-25 |
What the finished NCT03082287 record still lists
NCT03082287 is an observational study that tracks outcomes without assigning an intervention. The registered 424 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Fecal Calprotectin Level is the first listed.
NCT03082287 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03082287 about?
NCT03082287 is a clinical study titled "ALPCO Calprotectin ELISA - Measurement of Calprotectin Levels in Human Stool". The ALPCO Calprotectin ELISA is an in vitro diagnostic test intended to quantitatively measure concentrations of fecal calprotectin in human stool samples. Calprotectin is a protein biomarker of mucosal inflammation. Measurement of calprotectin can aid in the diagnosis of Inflammatory Bowel Diseases...
What is the current status of trial NCT03082287?
This trial is currently completed. The enrollment target is 424 participants. The study started on 2017-05-01. Estimated completion is 2019-10-25.
What interventions are being tested in trial NCT03082287?
The interventions under investigation include: Fecal Calprotectin Level (DEVICE).
Who is sponsoring clinical trial NCT03082287?
This trial is sponsored by American Laboratory Products Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05632770 · 424 participants · NA
A Deployment Focused Pragmatic Trial of Optimal Stepped Care Intervention Targeting PTSD and Comorbidity for Acutely Hospitalized Injury Survivors Treated in US Trauma Care Systems
- NCT05733767 · 424 participants · Phase 2
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
- NCT06978127 · 424 participants · NA
Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients
- NCT07140913 · 424 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI